Decoy Therapeutics Inc.: 10-K filed 2015-03-24
What Decoy Therapeutics Inc. reported in its annual report filed 2015-03-24 (fiscal FY 2014): 30 published measures, 51 facts as tagged in accession 0001615219-15-000004.
This filing
- Form
- 10-K (annual report)
- Filed
- 2015-03-24
- Fiscal period
- fiscal FY 2014
- Accession
- 0001615219-15-000004 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 35,611,398 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 1,118,571 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -6,538,340 | USD | |
| At 2014-02-26 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -3,742,049 | USD | 92 |
| 2014-02-26 to 2014-12-31 | -8,010,860 | USD | 309 |
| 2014-07-01 to 2014-09-30 | -1,986,437 | USD | 92 |
| 2014-04-01 to 2014-06-30 | -2,189,651 | USD | 91 |
| 2014-02-26 to 2014-03-31 | -92,723 | USD | 34 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | -6,480,866 | USD | 309 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | 76,141 | USD | 309 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | 40,411,160 | USD | 309 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | -76,141 | USD | 309 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | -8,010,860 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 85,144 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | 1,462,061 | USD | 309 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 34,224,549 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 1,067,161 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 578,653 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 3,751,411 | USD | 92 |
| 2014-02-26 to 2014-12-31 | 8,029,806 | USD | 309 |
| 2014-07-01 to 2014-09-30 | 1,993,363 | USD | 92 |
| 2014-04-01 to 2014-06-30 | 2,192,309 | USD | 91 |
| 2014-02-26 to 2014-03-31 | 92,723 | USD | 34 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 1,965,121 | USD | 92 |
| 2014-02-26 to 2014-12-31 | 4,003,911 | USD | 309 |
| 2014-07-01 to 2014-09-30 | 909,123 | USD | 92 |
| 2014-04-01 to 2014-06-30 | 1,099,644 | USD | 91 |
| 2014-02-26 to 2014-03-31 | 30,023 | USD | 34 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 2,215,711 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 1,472,299 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 97,141 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 11,997 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 50,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 15,442 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 370,396 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-12-31 | 163,019 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | -3,751,411 | USD | 92 |
| 2014-02-26 to 2014-12-31 | -8,029,806 | USD | 309 |
| 2014-07-01 to 2014-09-30 | -1,993,363 | USD | 92 |
| 2014-04-01 to 2014-06-30 | -2,192,309 | USD | 91 |
| 2014-02-26 to 2014-03-31 | -92,723 | USD | 34 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | -8,010,860 | USD | 309 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | -8,010,860 | USD | 309 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-10-01 to 2014-12-31 | 1,786,290 | USD | 92 |
| 2014-02-26 to 2014-12-31 | 4,025,895 | USD | 309 |
| 2014-07-01 to 2014-09-30 | 1,084,240 | USD | 92 |
| 2014-04-01 to 2014-06-30 | 1,092,665 | USD | 91 |
| 2014-02-26 to 2014-03-31 | 62,700 | USD | 34 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | 11,997 | USD | 309 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-02-26 to 2014-12-31 | 254,253 | USD | 309 |
Inspect the source
- Entity
- Decoy Therapeutics Inc. / CIK 0001615219
- Captured
- 2026-09-21T17:20:32.388Z
- SEC response SHA-256
3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))